The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Preventing CKD in patients with diabetes: Exploring the current and future role of GLP-1 RAs
This educational program consists of three presentations on the current and future role of GLP-1RA in patients with T2DM and CKD.This course consists of the following:New insights and guidelines for the management of CKD and diabetes - Prof. Johannes Mann - Munich, GermanyWhat is relevant for nephrology with regard to GLP-1RA in CVD? - Prof. Filip Knop, MD, PhD -- Copenhagen, DenmarkWhich patients with CKD and diabetes will benefit from management with GLP-1RA? - Prof. Katherine Tuttle, MD -- Spokane, WA, USAThe programme is available as enduring video, CME course and podcast